Davalintide
From PeptidePlaza, the free peptide reference · Entry #1112 · Metabolic · Sources fetched 2026-09-11 · Editorial standards
Davalintide (also known as davalintidum, davalintida, AC 2307, DACRA) is a metabolic research peptide. Davalintide is a calcitonin gene-related peptide type 1 receptor agonist and an amylin receptor AMY1, CALCR/RAMP1 agonist.
Davalintide, also known as AC 2307, is a peptide that acts as an agonist for both the calcitonin gene-related peptide type 1 receptor and the amylin receptor AMY1, CALCR/RAMP1. This dual mechanism of action has led to its investigation in metabolic conditions. It is currently in Phase 2 clinical trials for the treatment of obesity. Research into davalintide and similar compounds has explored its potential to improve glucose control and reduce body weight, as evidenced by studies in rodents. The compound is also discussed in the context of future pharmacotherapy for obesity and current drug targets in obesity pharmacotherapy.
1 Mechanism of action
Calcitonin gene-related peptide type 1 receptor agonist (agonist); Amylin receptor AMY1, CALCR/RAMP1 agonist (agonist)
Primary targets: Calcitonin gene-related peptide type 1 receptor · Amylin receptor AMY1, CALCR/RAMP1
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Obesity
3 Chemical and physical properties
| CAS number | 863919-85-1 |
|---|---|
| Molar mass | 3624.0 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Calcitonin gene-related peptide type 1 receptor, Amylin receptor AMY1, CALCR/RAMP1 |
4 Research studies (8)
- Amyloidogenicity of peptides targeting diabetes and obesity
Colloids and surfaces. B, Biointerfaces (2022) · Review - Islet amyloid polypeptide does not suppress pancreatic cancer
Molecular metabolism (2023) - Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids
PloS one (2013) - Current Drug Targets in Obesity Pharmacotherapy - A Review
Current drug targets (2017) · Review - Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Current obesity reports (2018) · Review - Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide
Diabetes, obesity & metabolism (2011) - Pharmacological management of appetite expression in obesity
Nature reviews. Endocrinology (2010) · Review - Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight
International journal of obesity (2005) (2010)
5 Safety and risk profile
5.1 Regulatory status
Davalintide is currently classified as Phase 2 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is Davalintide?
- Davalintide is a peptide that functions as an agonist for the calcitonin gene-related peptide type 1 receptor and the amylin receptor AMY1, CALCR/RAMP1. It is also known by the alias AC 2307.
- How does Davalintide work?
- Davalintide works by activating the calcitonin gene-related peptide type 1 receptor and the amylin receptor AMY1, CALCR/RAMP1. This dual agonism is the basis for its therapeutic potential in metabolic disorders.
- What is Davalintide used for?
- Davalintide is currently being studied for its potential use in treating obesity. It has reached Phase 2 clinical trials for this indication.
- What is the regulatory status of Davalintide?
- Davalintide is currently in Phase 2 clinical development. This means it is undergoing further testing to evaluate its efficacy and safety for its intended use.
7 References
- Davalintide — compound summary PubChem. View source
- Davalintide — molecule record ChEMBL. View source
- Davalintide — published literature (12 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Davalintide.
Shares amylin and amy1 pharmacology
A lipidated amylin analogue engineered to resist the amyloid fibrillation that plagues native human amylin. Works on satiety pathways entirely separate from GLP-1 — which is why it stacks so effectively with semaglutide.
Shares amylin and calcitonin pharmacology
The first amylin + GLP-1 fixed-dose combination to reach phase 3. Two satiety systems in one weekly injection, and the closest any injectable has come to bariatric-surgery-range weight loss.
Also metabolic
Gastrin is an endogenous human peptide that stimulates the stomach mucosa to produce and secrete hydrochloric acid and the pancreas to secrete digestive enzymes.
Also metabolic
Ghrelin is a peptide hormone that acts as a ligand for the growth hormone secretagogue receptor (GHSR). It is involved in regulating appetite, metabolism, and growth hormone release.
Also metabolic
Seractide Acetate is a synthetic peptide that acts as a melanocortin receptor 2 agonist.
Also metabolic
Parathyroid Hormone is an 84-residue peptide that acts as a parathyroid hormone receptor agonist. It is FDA approved and marketed as Bestmade Natural Products BM67.